Abstract
Cancer is a major cause of death worldwide, with over ten million fatalities reported each year. Common cancer treatments involve surgical procedures, radiation, and chemotherapeutic drugs. However, these treatments can cause toxicity in patients and may also harm healthy cells. As a result, scientists are exploring ways to selectively target cancer cells without damaging healthy cells. Intratumor heterogeneity, which refers to the diversity of cancer cells within a tumor, poses a significant challenge to effective cancer treatment. Nevertheless, advancements in diagnostic technologies and a better understanding of the molecular basis of tumors can potentially enhance the treatment of different types of cancer.
Cancer is a condition in which cells grow uncontrollably and evade cell death, leading to the formation of a tumor, except in the case of hematological cancers. The tumor grows by developing new blood vessels and eventually gains the ability to spread to other areas of the body, resulting in metastasis and death. Cancer can be caused by genetic mutations resulting from either inherited or environmental factors. For localized and nonmetastatic cancers, surgery and radiotherapy are the primary treatments. However, for metastatic cancers, chemotherapy, hormone therapy, and biological therapy are used. Chemotherapy works by inhibiting the growth of rapidly dividing cells, which is a characteristic of cancer cells. Unfortunately, chemotherapy also affects normal cells that have a high proliferation rate, such as hair follicles, bone marrow, and gastrointestinal tract cells, resulting in unwanted side effects. The need for targeted treatments based on the molecular changes of tumor cells arises from the indiscriminate destruction of normal cells, the toxicity of conventional chemotherapy, and the development of multidrug resistance.
The cancer diagnosis and treatment field are rapidly evolving, and there have been many exciting developments in recent years. While much work remains to be done, these advances offer hope for improving patient outcomes and ultimately finding a cure for this devastating disease.
This is a preview of subscription content, log in via an institution to check access.
References
Adashek JJ, Janku F, Kurzrock R (2021) Signed in blood: circulating tumor dna in cancer diagnosis, treatment and screening. Cancers. https://doi.org/10.3390/cancers13143600
Agashe R, Kurzrock R (2020) Circulating tumor cells: from the laboratory to the cancer clinic. Cancers. https://doi.org/10.3390/cancers12092361
Ambrosini R, Wang P, Kolar B, O’Dell W (2008) Computer-aided detection of metastatic brain tumors using automated 3-D template matching [abstract]. Proc Intl Soc Mag Reson Med 16:3414
Atkins MB, Lotze MT, Dutcher JP et al (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17(7):2105–2116. https://doi.org/10.1200/JCO.1999.17.7.2105
Banko P, Lee SY, Nagygyorgy V et al (2019) Technologies for circulating tumor cell separation from whole blood. J Hematol Oncol 12:48
Bell CJ, Dinwiddie DL, Miller NA et al (2011) Carrier testing for severe childhood recessive diseases by next-generation sequencing. Sci Transl Med 3:65ra4
Brown TM, Fee E (2006) Rudolf Carl Virchow. Am J Public Health 96(12):2104–2105. https://doi.org/10.2105/AJPH.2005.078436
Castellino RA (2005) Computer aided detection (CAD): an overview. Cancer Imaging 5:17–19
Chan KA, Jiang P, Chan CW, Sun K, Wong J, Hui EP, Chan SL, Chan WC, Hui DS, Ng SS (2013) Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. Proc Natl Acad Sci 110:18761–18768
Chen H, Zhang Z, Wang B (2018) Size- and deformability-based isolation of circulating tumor cells with microfluidic chips and their applications in clinical studies. AIP Adv 8:120701
Chinen AB, Guan CM, Ferrer JR, Barnaby SN, Merkel TJ, Mirkin CA (2015) Nanoparticle probes for the detection of cancer biomarkers, cells, and tissues by fluorescence. Chem Rev 115:10530–10574. https://doi.org/10.1021/acs.chemrev.5b00321
D’Errico G, Machado HL, Sainz B (2017) A current perspective on cancer immune therapy: step-by-step approach to constructing the magic bullet. Clin Transl Med 6(1):3. https://doi.org/10.1186/s40169-016-0130-5
Dong H, Strome SE, Salomao DR et al (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8(8):793–800. https://doi.org/10.1038/nm730
Faas BH, de Ligt J, Janssen I et al (2012) Non-invasive prenatal diagnosis of fetal aneuploidies using massively parallel sequencing-by-ligation and evidence that cell-free fetal DNA in the maternal plasma originates from cytotrophoblastic cells. Expert Opin Biol Ther 12(Suppl 1):S19–S26
Ferreira MM, Ramani VC, Jeffrey SS (2016) Circulating tumor cell technologies. Mol Oncol 10:374–394
Finn OJ (2008) Cancer immunology. N Engl J Med 358(25):2704–2715. https://doi.org/10.1056/NEJMra072739
Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13(3):688–696. https://doi.org/10.1200/JCO.1995.13.3.688
Hao SJ, Wan Y, Xia YQ et al (2018) Size-based separation methods of circulating tumor cells. Adv Drug Deliv Rev 125:3–20
Hawkes N (2019) Cancer survival data emphasise importance of early diagnosis. BMJ 364:l408. https://doi.org/10.1136/bmj.l408
Hu Z et al (2019) Quantitative evidence for early metastatic seeding in colorectal cancer. Nat Genet 51:1113–1122
Hui P (2014) Next generation sequencing: chemistry, technology and applications. Top Curr Chem. 336:1–18. https://doi.org/10.1007/128_2012_329. PMID: 22648865
Liang M, Tang W, Xu DM et al (2016) Low-dose CT screening for lung cancer: computer-aided detection of missed lung cancers. Radiology 281:279–288
Lotze MT, Frana LW, Sharrow SO, Robb RJ, Rosenberg SA (1985) In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Immunol 134(1):157–166
Lotze MT, Custer MC, Sharrow SO, Rubin LA, Nelson DL, Rosenberg SA (1987) In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration. Cancer Res 47(8):2188–2195
Luo H, Sun C, Sun Y et al (2011) Analysis of the transcriptome of Panax notoginseng root uncovers putative triterpene saponin-biosynthetic genes and genetic markers. BMC Genomics 12(Suppl 5):S5
Marchetti A, Del GM, Filice G et al (2012) Complex mutations & subpopulations of deletions at exon 19 of EGFR in NSCLC revealed by next generation sequencing: potential clinical implications. PLoS One 7:e42164
Maude SL et al (2018) Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 378:439–448. https://doi.org/10.1056/NEJMoa1709866
McGuire AL, Caulfield T, Cho MK (2008) Research ethics and the challenge of whole-genome sequencing. Nat Rev Genet 9:152–156
Miliotou AN, Papadopoulou LC (2018) CAR T-cell therapy: a new era in cancer immunotherapy. Curr Pharm Biotechnol 19(1):5–18. https://doi.org/10.2174/1389201019666180418095526
Neelapu SS et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377:2531–2544. https://doi.org/10.1056/NEJMoa1707447
Ozretic L, Heukamp LC, Odenthal M et al (2012) The role of molecular diagnostics in cancer diagnosis and treatment. Onkologie 35(Suppl 1):8–12
Pabla N, Dong Z (2012) Curtailing side effects in chemotherapy: a tale of PKCδ in cisplatin treatment. Oncotarget 3(1):107–111. https://doi.org/10.18632/oncotarget.439
Pantel K, Alix-Panabières C (2010) Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med 16:398–406
Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252–264. https://doi.org/10.1038/nrc3239
Pecot CV, Bischoff FZ, Mayer JA et al (2011) A novel platform for detection of CK+ and CK- CTCs. Cancer Discov 1:580–586
Perakis S, Speicher MR (2017) Emerging concepts in liquid biopsies. BMC Med 15:1–12
Plouffe BD, Murthy SK, Lewis LH (2015) Fundamentals and application of magnetic particles in cell isolation and enrichment: a review. Rep Prog Phys 78:016601
Rosenberg SA, Yang JC, Topalian SL et al (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271(12):907–913. https://doi.org/10.1001/jama.1994.03510360033032
Schuster SJ et al (2017) Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med 377:2545–2554. https://doi.org/10.1056/NEJMoa1708566
Siravegna G, Marsoni S, Siena S, Bardelli A (2017) Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol 14:531–548
Smith BC, McAndrew T, Chen Z et al (2012) The cervical microbiome over 7 years and a comparison of methodologies for its characterization. PLoS One 7:e40425
Smyth MJ, Ngiow SF, Ribas A, Teng MWL (2016) Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol 13(3):143–158. https://doi.org/10.1038/nrclinonc.2015.209
Turajlic S et al (2018) Tracking cancer evolution reveals constrained routes to metastases: TRACERx Renal. Cell 173:581–594.e512
van Middendorp JJ, Sanchez GM, Burridge AL (2010) The Edwin Smith papyrus: a clinical reappraisal of the oldest known document on spinal injuries. Eur Spine J 19(11):1815–1823. https://doi.org/10.1007/s00586-010-1523-6
Walter FM, Rubin G, Bankhead C, Morris HC, Hall N, Mills K, Dobson C, Rintoul RC, Hamilton W, Emery J (2015) Symptoms and other factors associated with time to diagnosis and stage of lung cancer: aprospective cohort study. Br J Cancer 112:S6–S13
Wei X, Ju X, Yi X et al (2011) Identification of sequence variants in genetic disease-causing genes using targeted next-generation sequencing. PLoS One 6:e29500
Welch JS, Link DC (2011) Genomics of AML: clinical applications of next-generation sequencing. Hematology Am Soc Hematol Educ Program 2011:30–35
Yang D, Khan S, Sun Y et al (2011) Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 306:1557–1565
Zhang Y, Li M, Gao X, Chen Y, Liu T (2019) Nanotechnology in cancer diagnosis: progress, challenges, and opportunities. J Hematol Oncol 12:137. https://doi.org/10.1186/s13045-019-0833-3
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2023 Springer Nature Singapore Pte Ltd.
About this entry
Cite this entry
Bairmani, Z.A., Alfroukh, K.M.A., Bairmani, F.A., Singh, J., Gandhi, V.V. (2023). Recent Developments in Cancer Detection and Treatment. In: Sobti, R.C., Ganguly, N.K., Kumar, R. (eds) Handbook of Oncobiology: From Basic to Clinical Sciences. Springer, Singapore. https://doi.org/10.1007/978-981-99-2196-6_10-1
Download citation
DOI: https://doi.org/10.1007/978-981-99-2196-6_10-1
Received:
Accepted:
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-99-2196-6
Online ISBN: 978-981-99-2196-6
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences